Pharmacologic treatment with CPI-613 and PS48 decreases mitochondrial membrane potential and increases quantity of autolysosomes in porcine fibroblasts | Scientific Reports
The Pyruvate Dehydrogenase Complex in Cancer: Implications for the Transformed State and Cancer Chemotherapy | IntechOpen
Prolongation of survival induced by four doses of CPI-613 (25 mg/kg),... | Download Scientific Diagram
Cornerstone Pharmaceuticals Lead Compound CPI-613
A strategically designed small molecule attacks alpha-ketoglutarate dehydrogenase in tumor cells through a redox process | SpringerLink
CPI-613 rewires lipid metabolism to enhance pancreatic cancer apoptosis via the AMPK-ACC signaling | Journal of Experimental & Clinical Cancer Research | Full Text
Mitochondria in cancer metabolism, an organelle whose time has come? - Abstract - Europe PMC
Selectively Targeting Metabolism in Mitochondria In Cancer Cells | Cancer Biology
Devimistat - Wikipedia
CPI-613 Supplier | CAS 95809-78-2 | Focus Biomolecules
Devimistat - Wikipedia
A comprehensive analysis of clinical trials in pancreatic cancer: what is coming down the pike? | Oncotarget
A Phase II Clinical Trial of CPI-613 in Patients with Relapsed or Refractory Small Cell Lung Carcinoma
A phase I study of the first-in-class antimitochondrial metabolism agent, CPI-613, in patients with advanced hematologic malignancies. - Abstract - Europe PMC
Finding Targets in Cancer's Metabolic Quirks
Devimistat (CPI-613) | デヒドロゲナーゼ 阻害剤
Devimistat | CPI-613 | CAS#95809-78-2 | Antineoplastic | MedKoo Biosciences
An integrated in vivo and in silico analysis of the metabolism disrupting effects of CPI-613 on embryo-larval zebrafish (Danio rerio) - ScienceDirect
The Mitochondrion as an Emerging Therapeutic Target in Cancer: Trends in Molecular Medicine
Predictive targeting of mitochondrial metabolism in Acute Myeloid Leukemia patients with a lipoic acid analog | medRxiv
CPI-613 | CAS:95809-78-2 | PDH/α-KGDH inhibitor | High Purity | Manufacturer BioCrick
Predictive targeting of mitochondrial metabolism in Acute Myeloid Leukemia patients with a lipoic acid analog | medRxiv
Cancers | Free Full-Text | The Metabolic Inhibitor CPI-613 Negates Treatment Enrichment of Ovarian Cancer Stem Cells
CPI-613 (Devimistat) | ≥99%(HPLC) | Dehydrogenase Inhibitor | AdooQ®
